Entity > Corporation > US > New York City New York > Athersys

About Athersys

Athersys, Inc. is an international biotechnology company that is focused in the field of regenerative medicine. They are committed to developing therapeutic products that they believe have best-in-class potential, meaning therapies that have the potential to be safer and more effective than the current standard of care or other products in development, and that may have other advantages, such as superior scalability or ease of administration.

Athersys is Developing the MultiStem Cell Therapy: MultiStem cell therapy, a patented and proprietary allogeneic “off-the-shelf” stem cell product, is our lead platform product and has shown promise for treating indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as certain other critical care conditions. MultiStem is currently being evaluated in several clinical-stage programs.

Athersys' Business Strategy: Their principal business objective is to discover, develop and commercialize novel therapeutic products for disease indications that represent significant areas of clinical need and where they believe there is a substantial commercial opportunity.

Founding: Athersys was founded in 1995. They are headquartered in Cleveland, Ohio.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Athersys

Company Attribute Value
Address StreetAddress: 3201 Carnegie Ave, AddressLocality: Cleveland, AddressRegion: Ohio, PostalCode: 44115, AddressCountry: United States
Founding Date 1995
Name Athersys
Number Of Employees 104
Revenue $8,426,000 USD
Ticker Symbol NASDAQ: ATHX
Url athersys
Facebook facebook
Linkedin linkedin
Twitter twitter
Google google
Wikidata wikidata



New York City, US
17 Sep 2023

New York City, US
17 Sep 2023


Page: 1 Desktop | Laptop Devices
Athersys, Inc.
Who We Are ... Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the ...
Athersys Inc (@athersys) · Twitter › news-and-media
News & Media
Athersys, Inc. Announces Pricing of $3.5 Million Public Offe... August 16, 2023. Athersys Reports Second Quarter 2023 Financial ... › investors
Here at Athersys, we have established a portfolio of therapeutic product development programs to address significant unmet medical need in several disease areas ... › quote › ATHX
Athersys, Inc. (ATHX) Stock Price, News, Quote & History
CLEVELAND, August 16, 2023--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care ... › company › athersys
Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat ... › quotes › ATHX
ATHX: Athersys Inc - Stock Price, Quote and News
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development ...
Entities Box
Entities Box
Stem cell companies
Related Searches
Related Searches
athersys buyout
Athersys stem cell therapy
athersys news
Knowledge Panel
Knowledge Panel

Athersys (Biotechnology company)

  • Stock price : ATHX (NASDAQ) $0.30 -0.13 (-30.23%)Sep 15, 4:00 PM EDT - Disclaimer
  • Parent organization : ABT Holding Co
  • Headquarters : Cleveland, OH
  • Subsidiaries : ABT Holding Co, Advanced Biotherapeutics, Inc
  • Founded : 1995
  • Ceo : Daniel Camardo

All information on this page is taken from publicly available sources, and the analysis we provide is a representation of Google's search results for the entity and does not represent any opinion or judgement about the entity by Kalicube itself. If you disagree with this analysis, please contact us and cite this reference : 89788